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1. INTRODUCTION {#cas13943-sec-0001}
===============

Colorectal cancer is the third most commonly occurring cancer worldwide and the second leading cause of cancer‐related deaths.[1](#cas13943-bib-0001){ref-type="ref"} In Japan, it is the most commonly occurring cancer in both sexes combined.[2](#cas13943-bib-0002){ref-type="ref"}, [3](#cas13943-bib-0003){ref-type="ref"} The 5‐year relative survival rate for metastatic colorectal cancer (mCRC) is approximately 12%‐13%.[4](#cas13943-bib-0004){ref-type="ref"} Thus, it is important to develop new, more effective therapies.

Vascular endothelial growth factor (VEGF) is overexpressed in primary colon tumors that have metastasized compared to those that have not.[5](#cas13943-bib-0005){ref-type="ref"} Furthermore, high VEGF expression predicts poor relapse‐free and overall survival of individuals with colorectal cancer.[6](#cas13943-bib-0006){ref-type="ref"} For this reason, VEGF has in recent years become a target for anti--cancer therapies, in combination with standard chemotherapy regimens folinic acid/5‐fluorouracil (5‐FU)/oxaliplatin (FOLFOX), FOLFOX/irinotecan (FOLFOXIRI) or 5‐FU/levofolinate/irinotecan (FOLFIRI). One anti--VEGF agent, bevacizumab, specifically blocks VEGF‐A and, in combination with FOLFOX,[7](#cas13943-bib-0007){ref-type="ref"} FOLFOXIRI[8](#cas13943-bib-0008){ref-type="ref"}, [9](#cas13943-bib-0009){ref-type="ref"} or FOLFIRI,[10](#cas13943-bib-0010){ref-type="ref"} has been shown to increase survival of patients with mCRC.

Aflibercept, also known as VEGF‐trap or ziv‐aflibercept, is a relatively new anti--VEGF agent.[11](#cas13943-bib-0011){ref-type="ref"} It is a recombinant fusion protein containing portions of the extracellular domains of human VEGF receptors 1 and 2. Unlike bevacizumab, which binds only to VEGF‐A, aflibercept binds to VEGF‐A, VEGF‐B and placental growth factor, thus blocking their downstream activity.

Several clinical trials have demonstrated the relative safety and efficacy of aflibercept plus FOLFIRI. The largest trial to date was an international randomized double‐blind phase III study conducted outside of Japan (VELOUR study \[NCT00561470\]),[12](#cas13943-bib-0012){ref-type="ref"} which consisted of 1226 patients with mCRC who had previously received oxaliplatin. Aflibercept plus FOLFIRI significantly improved both overall survival (OS; 13.50 vs 12.06 months, *P *=* *.0032) and progression‐free survival (PFS; 6.90 vs 4.67 months, *P *=* *.0001) compared to placebo plus FOLFIRI. Likewise, in a recently published randomized Phase III study of patients from the Asia‐Pacific region, aflibercept plus FOLFIRI improved both OS (14.59 vs 11.93 months, hazard ratio: .794) and PFS (6.93 vs 5.59 months, hazard ratio: .629) compared to placebo plus FOLFIRI (NCT01661270).[13](#cas13943-bib-0013){ref-type="ref"} A phase I dose‐escalation study of aflibercept plus FOLFIRI (NCT00921661)[14](#cas13943-bib-0014){ref-type="ref"} was conducted in Japanese patients with mCRC. No dose‐limiting toxicities or major safety issues were observed for 4 mg/kg aflibercept, the standard dose.

The objectives of the current phase II study were to assess the efficacy, safety and pharmacokinetics (PK) of aflibercept plus FOLFIRI as a second‐line treatment for mCRC in Japanese patients.

2. METHODS {#cas13943-sec-0002}
==========

2.1. Patients {#cas13943-sec-0003}
-------------

Inclusion criteria were: histologically or cytologically proven adenocarcinoma of the colon or rectum; measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; inoperable metastatic disease; 1 prior chemotherapeutic, oxaliplatin‐containing regimen for metastatic disease, during which or within 6 months after completion of which the disease progressed or patients relapsed; Eastern Cooperative Oncology Group performance status of 0 or 1; adequate organ function; and signed, dated informed consent. Exclusion criteria included active infectious disease, gastrointestinal ulcer, bleeding, urine protein‐creatinine ratio \>1, and uridine‐5‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1) genotype of \*6/\*6, \*28/\*28 or \*6/\*28.

2.2. Study design {#cas13943-sec-0004}
-----------------

This was a prospective, multicenter, open‐label, single‐arm study (Figure [1](#cas13943-fig-0001){ref-type="fig"}). All patients received the following treatment regimen once every 2 weeks: aflibercept (4 mg/kg) over 1‐2 hours by intravenous (i.v.) infusion; then levofolinate (200 mg/m^2^) over 120 ± 20 minutes, plus irinotecan (180 mg/m^2^) over 90 ± 15 minutes, simultaneously by i.v. infusion; then 5‐FU (400 mg/m^2^) as a bolus over 2‐4 minutes; and then 5‐FU (2400 mg/m^2^) over 41‐46 hours by continuous i.v. infusion. Treatment was given until disease progression, unacceptable toxicity or patient withdrawal.

![A, Study design. This prospective, multicenter, open‐label, single‐arm study consisted of a baseline period, a treatment period and a post--treatment follow‐up period. During the follow‐up period, tumors were imaged every 6 ± 1 wk until disease progression. (a) For subjects under Vitamin K antagonist therapy. (b) Before infusion, 1, 4 and 24 h in cycle 1 and before infusion in cycles 2 and 3. (c) Before infusion in cycles 1 and 3. B, Flow chart of patient participation](CAS-110-1032-g001){#cas13943-fig-0001}

The primary endpoint was objective response rate (ORR). Secondary endpoints were PFS, OS, safety and PK.

2.3. Efficacy assessments {#cas13943-sec-0005}
-------------------------

Tumors were imaged every 6 ± 1 weeks and at the end‐of‐treatment visit 30 ± 3 days after the last study treatment. In the post--treatment follow‐up period, tumors were imaged every 6 ± 1 weeks until disease progression. Survival status was determined every 2 months. ORR was defined as the percentage of patients with either a complete response (CR) or partial response (PR) to study treatment, determined based on tumor assessment by an independent radiological review committee (IRRC) using RECIST version 1.1 criteria. PFS was defined as the time interval from the first study treatment administration to either the first observation of radiologically documented disease progression, determined based on tumor assessment by the IRRC, or death due to any cause, whichever came first. OS was defined as the time interval from the first study treatment administration to death due to any cause.

In an exploratory analysis, ORR, PFS and OS were compared in patients with mutated *KRAS* (exon 2) vs those with wild‐type *KRAS* and in patients with left‐sided primary tumors (descending colon, sigmoid colon, rectosigmoid colon and/or rectum) vs those with right‐sided primary tumors (caecum, ascending colon and/or transverse colon).

2.4. Safety assessments {#cas13943-sec-0006}
-----------------------

Safety assessments were performed as shown in Figure [1](#cas13943-fig-0001){ref-type="fig"} and included physical examination, evaluation of laboratory data and assessment of adverse events. Laboratory safety tests were performed at baseline, at every visit before treatment administration and at the end‐of‐treatment visit, and included hematology, biochemistry, urinalysis, coagulation and any other tests as clinically indicated. Laboratory abnormalities were recorded as adverse events only if they led to study treatment discontinuation or modification (eg, dose reduction, cycle delay or omission) and/or were serious (ie, were life‐threatening and/or resulted in hospitalization, disability and death). Adverse events assessed included treatment‐emergent adverse events (TEAE), serious adverse events and death.

For immunogenicity evaluation, blood samples were collected before aflibercept infusion in treatment cycles 1 and 3, at 30 ± 3 days and 90 ± 7 days after the last aflibercept infusion, and in cases of infusion‐related allergic reaction (Grade ≥ 2) or proteinuria (\>3.5 g/24 hours or of renal origin associated with hematuria). The presence of anti--aflibercept antibodies was evaluated in serum using a validated non--quantitative titer‐based bridging immunoassay. If the result was positive, then the presence of aflibercept‐neutralizing antibodies was evaluated using a non--quantitative competitive ligand‐binding assay.

2.5. Population pharmacokinetics {#cas13943-sec-0007}
--------------------------------

A population PK approach was used to estimate individual PK parameters for free and VEGF‐bound aflibercept in all 62 patients. Blood samples were obtained during treatment cycle 1: pre‐treatment, before the end of infusion (EOI) of aflibercept (1 hour), and 3, 23 and 335 hours (Day 14) after the EOI of aflibercept. Blood samples were also obtained pre‐dose of every odd‐numbered cycle, and 30 and 90 days after the last administration of aflibercept.

Plasma concentrations were measured by validated enzyme‐linked immunosorbent assays. Concentrations of VEGF‐bound aflibercept were expressed as the free aflibercept equivalent by multiplying by 0.717, the ratio of the molecular weights of free and VEGF‐bound aflibercept. The lower limits of quantification (LLOQ) were 15.6 and (adjusted) 31.5 ng/mL, respectively.

The PK parameters were maximum concentration (*C* ~max~), area under the curve over the dosing interval (AUC~0‐14 day~), total body clearance (CL) and volume of distribution at steady state (*V* ~ss~) for free aflibercept, and CL for VEGF‐bound aflibercept.

2.6. Non--compartmental pharmacokinetics {#cas13943-sec-0008}
----------------------------------------

Pharmacokinetics parameters were calculated for irinotecan, its active metabolite SN‐38, and 5‐FU in the first 10 patients by non--compartmental analysis (PKDMS Version 2 running with WinNonLin Professional, Version 5.2.1, PharSight, Raleigh‐Durham, NC, USA). Blood samples for irinotecan and SN‐38 were obtained before aflibercept infusion, just before EOI of irinotecan (1.5 hours), and 2, 4.5 and 23 hours after the start of irinotecan infusion during cycle 1. Blood samples for 5‐FU were obtained before the start of aflibercept infusion and 2.5, 21 and 45 hours after the start of 5‐FU infusion during cycle 1. Concentrations were measured using validated electrospray liquid chromatography tandem mass spectrometry for irinotecan, SN‐38 and 5‐FU (LLOQ: 10.0, 1.0 and 5.0 ng/mL, respectively).

The PK parameters for irinotecan and SN‐38 were *C* ~max~, time to reach *C* ~max~(*t* ~max~), AUC until last quantifiable time point (AUC~last~), AUC extrapolated to infinity (AUC), terminal elimination half‐life (*t* ~1/2z~) and metabolic ratio based on molecular weight (*R* ~met~). For irinotecan, CL and *V* ~ss~ were also estimated. For 5‐FU, steady‐state concentration during constant‐rate infusion (*C* ~ss~) and clearance at steady state (CL~ss~) were estimated.

2.7. Statistical analysis {#cas13943-sec-0009}
-------------------------

This study aimed to estimate the ORR in Japanese patients with mCRC at a certain precision. In prior studies of patients with mCRC treated in the second line with FOLFIRI or FOLFIRI plus aflibercept, ORR ranged from approximately 10% to 20%.[10](#cas13943-bib-0010){ref-type="ref"}, [11](#cas13943-bib-0011){ref-type="ref"}, [12](#cas13943-bib-0012){ref-type="ref"}, [13](#cas13943-bib-0013){ref-type="ref"}, [14](#cas13943-bib-0014){ref-type="ref"}, [15](#cas13943-bib-0015){ref-type="ref"}, [16](#cas13943-bib-0016){ref-type="ref"}, [17](#cas13943-bib-0017){ref-type="ref"} If the ORR observed in this study was in the same range, then 60 patients would provide precision (range of 95% CI) from 0.16 to 0.20.

The best objective response was summarized with descriptive statistics. ORR with its associated 95% CI was calculated using normal approximation based on the best objective response judged by the IRRC.

The median PFS, median OS, and their associated probability of survival at each time point and 95% CI were estimated using the Kaplan‐Meier method. The time points were every 3 months, for a total of 15 months for PFS and 24 months for OS.

For each laboratory parameter, a patient was considered evaluable if ≥1 measurement was available on treatment. Laboratory toxicities were graded from 1 (least severe) to 5 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and were summarized as "all grades" or "Grade ≥3." For patients with multiple occurrences of a particular laboratory parameter during the study treatment period, the maximum (worst) grade was used.

Treatment‐emergent adverse events were adverse events reported between the first study treatment infusion and 30 days after the last one. TEAE were summarized with respect to frequency and intensity/severity, as graded by the worst NCI CTCAE version 4.03 criteria. All TEAE were coded using the Medical Dictionary for Regulatory Activities version 18.0.

2.8. Ethical considerations {#cas13943-sec-0010}
---------------------------

The study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with all international and Japanese laws, regulations and guidelines. All aspects of the study were approved by the independent ethics committee and institutional review board. Patients were fully informed of the study and provided written consent. The study was registered with ClinicalTrials.gov with the identifier NCT01882868.

3. RESULTS {#cas13943-sec-0011}
==========

This study started when the first patient was enrolled in July 2013 and closed on the day of database lock in August 2015. Sixty‐two patients from 19 clinical sites in Japan were enrolled. Two patients were not evaluable for ORR: one had neither a target nor a non--target lesion, and one had only non--target lesions at baseline. The demographics and disease characteristics of the 60 evaluable patients appear in Table [1](#cas13943-tbl-0001){ref-type="table"}. Fifty evaluable patients (83.3%) had received prior bevacizumab.

###### 

Patient and disease characteristics at baseline

  Characteristic                                                       Value (N = 60)
  -------------------------------------------------------------------- ----------------
  Age in years                                                         
  Mean (SD)                                                            61.6 (9.8)
  Median                                                               62.5
  Min:Max                                                              39:78
  Age group in years (n \[%\])                                         
  \<65                                                                 33 (55.0)
  ≥65 but \<75                                                         24 (40.0)
  ≥75                                                                  3 (5.0)
  Sex (n \[%\])                                                        
  Male                                                                 34 (56.7)
  Female                                                               26 (43.3)
  Race (n \[%\])                                                       
  Asian/Oriental                                                       60 (100)
  Other                                                                0 (0)
  ECOG performance status (n \[%\])                                    
  0                                                                    40 (66.7)
  1                                                                    20 (33.3)
  Body weight in kg                                                    
  Mean (SD)                                                            59.67 (10.48)
  Median                                                               57.70
  Min:Max                                                              39.8:86.8
  Body surface area in m^2^                                            
  Mean (SD)                                                            1.626 (0.167)
  Median                                                               1.613
  Min:Max                                                              1.29:1.99
  Prior hypertension (n \[%\])                                         
  Yes                                                                  31 (51.7)
  No                                                                   29 (48.3)
  UGT1A genotype (n \[%\])[a](#cas13943-note-0002){ref-type="fn"}      
  Wild‐type                                                            
  \*1/\*1                                                              20(60.6)
  Heterozygous                                                         
  \*1/\*28                                                             4 (12.1)
  \*1/\*6                                                              9 (27.3)
  Complex heterozygous                                                 
  \*6/\*28                                                             0
  Homozygous                                                           
  \*28/\*28                                                            0
  \*6/\*6                                                              0
  Primary tumor location (n \[%\])                                     
  Left (descending colon, sigmoid, rectosigmoid, rectum)               45 (75.0)
  Right (caecum, ascending colon, transverse colon)                    15 (25.0)
  Histology type (n \[%\])                                             
  Adenocarcinoma                                                       60 (100)
  Histopathology                                                       
  Well or moderately differentiated                                    55 (91.7)
  Undifferentiated or poorly differentiated                            2 (3.3)
  Unknown                                                              3 (5.0)
  Number of metastatic organs                                          
  \>1                                                                  36 (60.0)
  1                                                                    24 (40.0)
  Liver metastasis only (n \[%\])                                      
  Yes                                                                  9 (15.0)
  No                                                                   51 (85.0)
  Prior bevacizumab (n \[%\])                                          
  Yes                                                                  50 (83.3)
  No                                                                   10 (16.7)
  Prior adjuvant therapy (n \[%\])                                     
  Yes                                                                  8 (13.3)
  No                                                                   52 (86.7)
  Time from 1st diagnosis to 1st study treatment administration (mo)   
  Mean (SD)                                                            18.79 (14.74)
  Median                                                               14.93
  Min:Max                                                              3.7:89.6

ECOG, Eastern Cooperative Oncology Group; UGT1A1, uridine‐5‐diphospho‐glucuronosyltransferase 1A1.

N = 33.

John Wiley & Sons, Ltd

As of the final database lock, all patients had discontinued study treatment (Figure [1](#cas13943-fig-0001){ref-type="fig"}). The median number of treatment cycles received per patient was 8.0 (range: 1‐31), and the median duration of study treatment exposure was 21.8 weeks (range: 2‐73 weeks). The median relative dose intensities were 72% for aflibercept, 65% for irinotecan and 71% for 5‐FU.

3.1. Efficacy {#cas13943-sec-0012}
-------------

Five of the 60 evaluable patients had PR and none had CR, resulting in an ORR of 8.3% (95% CI: 1.3%‐15.3%). In addition, 43 (71.7%) had stable disease, for an overall DCR of 80.0% (95% CI: 69.9%‐90.1%; see also Figure [2](#cas13943-fig-0002){ref-type="fig"}).

![Waterfall plot showing best objective response in 60 patients. CI, confidence interval; DCR, disease control rate; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease](CAS-110-1032-g002){#cas13943-fig-0002}

The other efficacy endpoints were evaluated for all 62 patients. The median PFS was 5.42 months (95% CI: 4.14‐6.70; Figure [3](#cas13943-fig-0003){ref-type="fig"}). As of the last tumor assessment, 47 (75.8%) patients had documented disease progression, 11 (17.7%) had died without disease progression and 4 (6.5%) had no disease progression. The median OS was 15.59 months (range: 11.20‐19.81 months; Figure [4](#cas13943-fig-0004){ref-type="fig"}). As of the final cutoff date, 21 (33.9%) patients had survived. The 2‐year survival rate was 28.2% (95% CI: 14.8%‐41.6%).

![Kaplan‐Meier curve of progression free survival](CAS-110-1032-g003){#cas13943-fig-0003}

![Kaplan‐Meier curve of overall survival](CAS-110-1032-g004){#cas13943-fig-0004}

Of the 62 patients, 26 had mutant *KRAS*, 29 had wild‐type *KRAS* and 7 had unknown *KRAS* status. Forty‐seven patients had a left‐sided primary tumor and 15 had a right‐sided tumor. The ORR, PFS and OS based on *KRAS* status and primary tumor location are shown in Table [S1](#cas13943-sup-0003){ref-type="supplementary-material"} and Figures [S1](#cas13943-sup-0001){ref-type="supplementary-material"} and [S2](#cas13943-sup-0002){ref-type="supplementary-material"}.

After discontinuing the study treatment, 51 (82.3%) patients received ≥1 further anti--cancer therapy, including 39 (62.9%) who received further biologics/small molecules (cetuximab: 9 \[14.5%\]; bevacizumab: 9 \[14.5%\]; regorafenib: 15 \[24.2%\]; panitumumab: 10 \[16.1%\]).

3.2. Safety {#cas13943-sec-0013}
-----------

Hematological abnormality occurred in most patients: leukopenia (87.1% of patients), neutropenia (85.5%), anemia (82.3%) and thrombocytopenia (62.9%) (Table [2](#cas13943-tbl-0002){ref-type="table"}). Of all clinical laboratory abnormalities assessed, an abnormal creatinine level was the most common, affecting 60 patients (96.8%). Proteinuria occurred in 51 patients (82.3%); of these cases, 22 (43.1%) occurred in treatment cycle 1.

###### 

Clinical laboratory abnormalities

  Clinical laboratory tests                   Abnormalities, n (%)   
  ------------------------------------------- ---------------------- -----------
  Hematological tests (N = 62)                                       
  Leukopenia                                  54 (87.1)              19 (30.6)
  Neutropenia                                 53 (85.5)              39 (62.9)
  Anemia                                      51 (82.3)              1 (1.6)
  Thrombocytopenia                            39 (62.9)              0
  Liver and renal tests (N = 62)                                     
  ALT                                         35 (56.5)              3 (4.8)
  AST                                         38 (61.3)              4 (6.5)
  Alkaline phosphatase                        45 (72.6)              3 (4.8)
  Total bilirubin                             20 (32.3)              2 (3.2)
  Creatinine                                  60 (96.8)              1 (1.6)
  Urine tests (N = 62)                                               
  Proteinuria                                 51 (82.3)              13 (21.0)
  UPCR                                                               
  ≤1[a](#cas13943-note-0004){ref-type="fn"}   37 (59.7)              --
  \>1, ≤2                                     10 (16.1)              --
  \>2, ≤3                                     5 (8.1)                --
  \>3                                         10 (16.1)              --
  Dipstick RBC                                                       
  \+                                          16 (25.8)              --
  ++                                          9 (14.5)               --
  +++                                         7 (11.3)               --
  ++++                                        1 (1.6)                --
  Metabolism tests (N = 62)                                          
  Hypoglycemia                                1 (1.6)                0
  Hyperglycemia                               49 (79.0)              1 (1.6)
  Hypoalbuminemia                             51 (82.3)              2 (3.2)
  Electrolyte tests (N = 62)                                         
  Hypocalcemia                                11 (17.7)              0
  Hypercalcemia                               5 (8.1)                0
  Hypokalemia                                 20 (32.3)              1 (1.6)
  Hyperkalemia                                17 (27.4)              0
  Hyponatremia                                25 (40.3)              2 (3.2)
  Hypernatremia                               5 (8.1)                0
  Hypophosphatemia                            21 (33.9)              4 (6.5)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; RBC, red blood cells; UPCR, urine protein‐creatinine ratio.

Includes UPCR in the normal range of 0 to \<0.15.

John Wiley & Sons, Ltd

All patients had ≥1 TEAE. Fifty‐six patients (90.3%) had Grade 3 or 4 TEAE; the most common TEAE were neutropenia, hypertension, diarrhea and decreased appetite (Table [3](#cas13943-tbl-0003){ref-type="table"}). Furthermore, 20 patients had ≥1 serious adverse event. Forty‐one (66.1%) patients died due to disease progression, all \>30 days after the last study treatment administration. No patients died as a result of treatment.

###### 

Most commonly reported treatment‐emergent adverse events

  Primary system organ class                              n (%)       
  ------------------------------------------------------- ----------- -----------
  Preferred term                                                      
   Any class                                              62 (100)    56 (90.3)
   Blood and lymphatic system disorders                   46 (74.2)   38 (61.3)
  Neutropenia                                             46 (74.2)   38 (61.3)
   Metabolism and nutrition disorders                     47 (75.8)   10 (16.1)
  Decreased appetite                                      46 (74.2)   8 (12.9)
   Nervous system disorders                               18 (29.0)   0
  Headache                                                7 (11.3)    0
   Vascular disorders                                     33 (53.2)   17 (27.4)
  Hypertension                                            29 (46.8)   17 (27.4)
   Respiratory, thoracic, and mediastinal disorders       45 (72.6)   2 (3.2)
  Epistaxis                                               25 (40.3)   0
  Dysphonia                                               18 (29.0)   0
  Cough                                                   7 (11.3)    0
  Hiccups                                                 7 (11.3)    0
   Gastrointestinal disorders                             56 (90.3)   18 (29.0)
  Diarrhea                                                42 (67.7)   12 (19.4)
  Nausea                                                  36 (58.1)   2 (3.2)
  Stomatitis                                              29 (46.8)   5 (8.1)
  Vomiting                                                17 (27.4)   0
  Constipation                                            10 (16.1)   0
  Abdominal pain                                          9 (14.5)    0
   Skin and subcutaneous tissue disorders                 44 (71.0)   1 (1.6)
  Alopecia                                                30 (48.4)   0
  Palmar‐plantar erythrodysesthesia syndrome              8 (12.9)    0
   Rash                                                   7 (11.3)    0
   Renal and urinary disorders                            19 (30.6)   6 (9.7)
  Proteinuria                                             19 (30.6)   6 (9.7)
   General disorders and administration site conditions   44 (71.0)   4 (6.5)
  Fatigue                                                 39 (62.9)   3 (4.8)
  Pyrexia                                                 13 (21.0)   0

John Wiley & Sons, Ltd

One patient was positive for anti--aflibercept antibodies at baseline (and positive in the neutralizing antibody assay); however, all subsequent samples from this patient were negative.

3.3. Pharmacokinetics {#cas13943-sec-0014}
---------------------

Population PK data (free and VEGF‐bound aflibercept) and non--compartmental PK data (irinotecan, SN‐38 and 5‐FU) appear in Table [4](#cas13943-tbl-0004){ref-type="table"}. Plasma concentrations for all 5 analytes are shown in Figure [5](#cas13943-fig-0005){ref-type="fig"}.

###### 

Summary of PK parameters in treatment cycle 1

  PK parameters[a](#cas13943-note-0006){ref-type="fn"}   Mean ± SD (CV%)
  ------------------------------------------------------ ---------------------
  Free aflibercept                                       
  *C* ~max~, μg/mL                                       73.2 ± 10.7 (15%)
  AUC~0‐14 d~, μg·day/mL                                 247 ± 41 (17%)
  Clearance, L/d                                         0.805 ± 0.178 (22%)
  *V* ~ss~, L                                            6.20 ± 1.11 (18%)
  VEGF‐bound aflibercept                                 
  Clearance, L/d                                         0.162 ± 0.014 (9%)
  Irinotecan                                             
  *C* ~max~, ng/mL                                       2220 ± 528 (24%)
  AUC, ng·h/mL                                           17 700 ± 6400 (36%)
  *t* ~1/2z~, h                                          5.19 ± 0.74 (14%)
  Clearance, L/h/m^2^                                    11.1 ± 3.2 (28%)
  *V* ~ss~, L/m^2^                                       55.7 ± 16.0 (29%)
  SN‐38[b](#cas13943-note-0007){ref-type="fn"}           
  *C* ~max~, ng/mL                                       32.2 ± 11.4 (36%)
  AUC, ng·h/mL                                           341 ± 72 (21%)
  *t* ~1/2z~, h                                          10.3 ± 3.1 (30%)
  5‐FU                                                   
  CL~ss~, L/h/m^2^                                       72.6 ± 40.4 (56%)

AUC~0‐14 d~, area under the concentration vs time curve 0‐14 d post start of infusion; CL~ss~, clearance at steady state; *C* ~max~, maximum plasma concentration observed; CV%, coefficient of variation; 5‐FU, 5‐fluorouracil; PK, pharmacokinetics; SD, standard deviation; *t* ~1/2z,~ terminal elimination half‐life; *V* ~ss~, volume of distribution at steady state.

N = 62 for free and vascular endothelial growth factor‐bound aflibercept. N = 10 for irinotecan, SN‐38 and 5‐FU, for which a non--compartmental PK analysis was performed after a 1‐h infusion of aflibercept (4 mg/kg).

Represented 3% of irinotecan exposure.

John Wiley & Sons, Ltd

![Plasma concentrations of study drugs over time in treatment cycle 1. Blood samples were collected from 10 patients before treatment cycle 1 and at various time points throughout cycle 1. Plasma concentrations of (A) free and vascular endothelial growth factor (VEGF)‐bound aflibercept were determined using validated enzyme‐linked immunosorbent assays. Plasma concentrations of (B) irinotecan, SN‐38 and (C) 5‐fluorouracil (5‐FU) were determined using validated electrospray liquid chromatography tandem mass spectrometry](CAS-110-1032-g005){#cas13943-fig-0005}

4. DISCUSSION {#cas13943-sec-0015}
=============

This study examined the efficacy, safety and PK of aflibercept plus FOLFIRI in Japanese patients with mCRC that was refractory or intolerant to a first‐line oxaliplatin‐containing regimen. The primary endpoint, ORR by the IRRC, was 8.3% (95% CI: 1.3%‐15.3%).

The ORR was lower than that in the VELOUR study (19.8%; 95% CI: 16.4%‐23.2%). Possible reasons for this discrepancy are differences between the study populations and the limited size of our study. Consistent with a lower ORR, the PFS in the current study was slightly shorter than that in the VELOUR study: 5.42 months (95% CI: 4.14‐6.70) vs 6.90 months (6.51‐7.20) overall.[12](#cas13943-bib-0012){ref-type="ref"} Based on these findings and the DCR of 80.0% (95% CI: 69.9%‐90.1%), adding aflibercept to FOLFIRI yielded results consistent with those of the VELOUR study. The ORR and PFS were also comparable to those in the Asia‐Pacific study[13](#cas13943-bib-0013){ref-type="ref"} (ORR = 8.3% \[95% CI: 1.3%‐15.3%\] vs 18% \[13.3%‐23.5%\] and PFS = 5.42 months \[4.14‐6.70\] vs 6.93 months \[6.045‐7.655\]).

The median OS of 15.59 months (95% CI: 11.20‐19.81) was similar to the median OS in both the VELOUR study[12](#cas13943-bib-0012){ref-type="ref"} (13.50 months; 95% CI: 12.52‐14.95) and the Asia‐Pacific study[13](#cas13943-bib-0013){ref-type="ref"} (14.59 months; 95% CI: 13.18‐16.46), with overlapping 95% CI. Neither the *KRAS* oncogene nor primary tumor sidedness significantly affected ORR, PFS or OS.

The safety profile was as expected of an anti--VEGF agent and was comparable to that observed in the VELOUR study. Together, the TEAE represent an enhancement of the toxicity profile associated with usage of FOLFIRI. The absence of a sample positive for anti--aflibercept antibodies post--treatment suggests that IV administration of 4 mg/kg aflibercept confers no immunogenicity in patients with mCRC.

The PK values of free aflibercept were comparable to those in previous studies for Chinese patients.[18](#cas13943-bib-0018){ref-type="ref"} Adding aflibercept to FOLFIRI did not significantly affect the PK of irinotecan, SN‐38 or 5‐fluorouracil: the PK values of these FOLFIRI components were comparable between the current study, in which aflibercept was added, and published studies in which it was not. For example, the clearance of irinotecan in the current study was similar to the values in the Gupta et al[19](#cas13943-bib-0019){ref-type="ref"} study and in the Satoh et al[20](#cas13943-bib-0020){ref-type="ref"} study. The AUC for irinotecan and SN‐38 overlaps[19](#cas13943-bib-0019){ref-type="ref"} or is slightly high.[20](#cas13943-bib-0020){ref-type="ref"} The clearance of 5‐FU in our study had a relatively large coefficient of variance (56%), consistent with studies showing that 5‐FU plasma clearance is widely variable among patients (reviewed by Lee et al[21](#cas13943-bib-0021){ref-type="ref"}). In previous population pharmacokinetic analyses, no clinically relevant drug‐drug interactions between aflibercept and irinotecan or fluorouracil were found.[22](#cas13943-bib-0022){ref-type="ref"} Likewise, no significant drug‐drug interactions were found in the current study.

A limitation of this study is its small sample size compared to that of the VELOUR study. In addition, unlike the VELOUR study, the current study had no control arm, so ability to compare the ORR results in the 2 studies is limited. Studies containing larger numbers of Japanese patients are needed to corroborate our findings.

In conclusion, adding aflibercept to FOLFIRI was shown to be beneficial and well‐tolerated in Japanese patients with mCRC.
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